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Highlights (3-5) 
• Enteroviral infection has been long-associated with type 1 diabetes in epidemiological 
studies 
• β-cells express a specific enteroviral receptor isoform, CAR-SIV, mainly on secretory 
granules 
• β-cells respond to enteroviruses by allowing the establishment of a persistent infection 
• Enteroviral vaccines are under development that might be effective in type 1 diabetes 
 
 
 
 
 
Abstract 
The development of islet autoimmunity and type 1 diabetes has long been linked with enteroviral 
infection but a causal relationship has proven hard to establish. This is partly because much of the 
epidemiological evidence derives from studies of neutralising antibody generation in blood samples 
while much less attention has been paid to the pancreatic beta cells as a site of infection. Nevertheless, 
recent studies have revealed that beta cells express specific enteroviral receptors and that they can 
sustain a productive enteroviral infection. Importantly, they can also mount antiviral responses which 
attenuate viral replication and may favour the establishment of a persistent enteroviral infection. 
Together, these responses combine to create the Trojan horse by which enteroviruses might 
precipitate islet autoimmunity.  
 
  
Type 1 diabetes (T1D) is characterised by the selective loss of insulin producing beta cells from the 
islets of Langerhans in the pancreas, meaning that affected individuals must administer exogenous 
insulin throughout their lives. The incidence of the disease is increasing [1] and although previously 
considered to be predominantly a disease of the young, it is now known to develop in all decades of life 
[2]. As a consequence, there are likely to be significant numbers of older individuals with T1D who 
have been mis-diagnosed with Type 2 diabetes (T2D). These two observations suggest that the number 
of people affected by T1D may be larger than previously thought.  
Type 1 diabetes arises from a complex interaction between genetic, immune and environmental factors 
which, as emphasized in comprehensive recent reviews [3,4] are poorly understood. In particular, the 
environmental influences have proven hard to identify, although studies as far back as the 1960’s have 
implicated viral infection, particularly by human enteroviruses (HEV; single-stranded RNA (+) viruses 
from the picornavirus family), as a potentially important factor both in the triggering of islet 
autoimmunity and the onset of clinical  disease. In support of this, a 2011 meta-analysis of 26 earlier 
studies, provided  evidence that  enteroviral infection occurred 3.7 times more commonly in individuals 
with islet autoimmunity and was 9.8 times more likely at disease onset when compared to matched 
controls [5]. Since that time, additional studies have emerged to support this hypothesis [6]. In 
particular, evidence that enterovirus infections are more frequent prior to the appearance of islet 
autoantibodies has been found in several large prospective cohort studies [7-10]. Importantly, recent 
studies of  unique pancreas biopsy samples from Norwegian patients with T1D (the DiViD samples 
[11]) have provided strong evidence for both the presence of HEV and enhanced islet anti-viral 
responses  in  newly-diagnosed patients [12-15].  In addition, ever more sensitive technologies are being 
developed to detect or interrogate viral infection and anti-viral responses in blood [8,16-20], islets 
[12,21,22], stool [9] and other tissues [23-31]. These are currently being applied in new collaborative 
studies involving multiple laboratories who are employing differing expertise and complementary 
technologies to examine blinded tissue samples available from the network of Pancreatic Organ Donors 
with Diabetes (nPOD). The first results are due for publication soon and are expected to provide 
additional support for the enteroviral hypothesis in T1D.  
Enteroviruses and beta cells: an unfortunate conjunction  
Human beta cells are known to be susceptible to infection with HEVs, particularly members of the 
Coxsackievirus B family. Thus, isolated human islets can be productively infected with a range of 
different EV-B family members (CVBs and Echoviruses, many of which have been associated with 
T1D; Table 1) in vitro. Furthermore, among the various islet cells, it is the beta cells that are 
preferentially susceptible to infection [32-34], and this leads to a dramatic decrement in glucose-
induced insulin secretion [21,35,36]. Tropism of HEVs for the islets has also been demonstrated in vivo 
in the pancreata of neonates who died following a lethal CVB infection [6,34,37] and in the pancreas 
of individuals with T1D [38,39]. This then raises the question: “so why the beta cells?”  
The tropism of the virus for the beta cell is likely to be driven by at least two factors; first, these cells 
express receptors necessary for the binding and subsequent internalisation of the virus and secondly, 
they contain specific host factors which the virus can hijack to facilitate successful infection, replication 
and, perhaps, persistence. This latter point is interesting since the traditional view states that 
enteroviruses are not likely to establish persistent infections and this concept will be explored further 
below. The various potential receptors utilised by enteroviruses which are expressed in human islets are 
summarised in Table 2 but one that is receiving particular attention is the Coxsackie and Adenovirus 
Receptor (CAR). This molecule is utilised as an entry vehicle by many of the viruses that are associated 
with T1D in epidemiological studies and very recently we have shown that a specific isoform of CAR, 
having a unique C-terminal PDZ binding domain (CAR-SIV) is selectively and highly expressed within 
the beta cell [40]. Studies by Ylipaasto et al, have also demonstrated that infection of human islets with 
CVB4 and CVB5 was effectively prevented in the presence of an antibody that blocks CAR [41]. 
Intriguingly, in our work, the subcellular localisation of CAR-SIV was unusual in that it was not present 
primarily at the plasma membrane of beta cells, as might be expected, but rather it was located mainly 
in insulin secretory granules. This unexpected localisation implies that the virus could selectively enter 
the beta cell by a Trojan horse mechanism in which secretory granule proteins are hijacked as they 
emerge onto the cell surface during exocytosis, such that virus particles are then internalized by the 
endocytic machinery during membrane recovery (Figure 1). In support of this, electron microscopy 
studies by Frisk et al of human islets infected with CVBs clearly show the presence of viral replication 
complexes and newly synthesised virions at, or near, insulin granule membranes [35]. 
In recent years, a series of critical host factors required for successful HEV infections have 
been identified. These include PLA2G16 [42] which is essential for  virion-mediated genome delivery 
into the cytoplasm; phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) and its product phosphatidylinositol-
4-phosphate (PI4P), which are critical for the generation of specialised organelles required for efficient 
viral replication [43,44]); polypyrimidine tract-binding protein 1 (PTBP1),  which is utilized by the 
virus to promote cap-independent translation of viral RNA [36] and heat shock protein 90 (HSP90), 
which is required for the correct processing of the capsid precursor P1 [45]. Importantly, many of these 
proteins are expressed in human beta cells and play a key role in pathways unique to beta cells (reviewed 
in [46]). For example, PTBP1, has an important role in glucose-stimulated cap-independent translation 
of insulin granule proteins [36]; PI4KIIIβ acts as a metabolic sensor in beta cells and regulates the 
priming of secretory granules [47] and HSP90 is a chaperone that regulates surface expression of ATP-
sensitive potassium (KATP) channels [48]. Together these results suggest that human beta cells express 
specific virus entry receptors as well as key host factors that aid the virus at various points in its 
lifecycle. This may therefore help to explain their exquisite sensitivity to infection.  
In parallel with these considerations, it is also important to note that beta cells are terminally 
differentiated and studies of their neogenesis and proliferation suggest that these processes are 
vanishingly rare in humans after the age of 10y [49,50]. This means that the human host must develop 
strategies to effectively manage, or preferably clear, any beta cell viral infection, whilst doing 
everything possible to minimise the destruction of these largely irreplaceable cells. In this context, it is 
well known that beta cells are extremely sensitive to interferons (IFNs), the principal anti-viral 
cytokines produced in response to an infection [51,52]. As viremia (viruses in the bloodstream) must 
occur prior to infection of the beta cells it is likely that any cells targeted during the initial acute phase 
of infection will elaborate IFNs. Thus, the pancreas will be exposed to IFNs prior to any encounter with 
the virus and this may serve to prime the beta cells to resist infection.  Indeed, pre-treatment of islets 
with Type I and III IFNs promotes an anti-viral state and significantly reduces viral replication 
following infection in vitro [51,52].  However, IFNs do not  necessarily block viral entry, which could 
yield a scenario in which virus has entered the cell, yet the host cell has succeeded in upregulating a 
range of  anti-viral proteins that will counter any attempt by that virus to establish a productive, lytic, 
infection [53]. Conceivably, a battle then ensues between the host (beta) cell and the virus which 
culminates in a mutual compromise where viral persistence is established and the host cells remain 
viable (Figure 2). In support of this hypothesis, risk-associated single nucleotide polymorphisms (SNPs) 
for T1D are found in key anti-viral response genes such as IFIH1 and TYK2. Individuals carrying these 
SNPs exhibit altered IFN responses [54-61] and the risk variants have been associated with an increased 
frequency of HEV infection [62]. Furthermore, of the 51 identified candidates genes associated with 
T1D, 42 are expressed in human beta cells and when Ingenuity Pathway Analysis was performed on 
these genes, the three highest scoring canonical pathways were - Interferon signalling, Role of JAK1, 
JAK2 and TYK in interferon signalling and Role of pattern recognition receptors in recognition of virus 
and bacteria [54].  These pathways are all activated in response to viral infections and this provides a 
firm link between genetic predisposition to T1D and host anti-viral responses. 
Evidence for persistence of HEV infection 
Traditionally, HEVs are thought to induce an acute infection in which large numbers of new viral 
particles are rapidly synthesized and release from infected cells to spread to other nearby host cells. 
One of the most effective host mechanisms to control HEVs infection is the generation of neutralising 
antibodies (detected as early as 7 days after infection), which help to clear the virus from the circulation 
and affected tissues.  However, there is mounting evidence that HEVs can evade these primary defense 
mechanisms to establish a lower level, persistent, infection under certain circumstances. Indeed, this 
type of infection has now been associated with several diseases such as Chronic Fatigue Syndrome 
(CFS) [63]; chronic myocarditis and dilated cardiomyopathy [64] and Amyotrophic Lateral Sclerosis 
(ALS; reviewed in [65]) as well as Type 1 diabetes. In order to understand this previously unrecognized 
aspect of EV biology, a number of mechanisms have been proposed to explain how the virus might 
persist. These include the activation of processes to restrict viral RNA replication, including by deletion 
of nucleotides from within the 5’UTR of the viral RNA genome [64,66-68]  and equalization of the 
proportions of positive and negative strands to form double stranded RNA (dsRNA) molecules [69,70]. 
A key additional requirement is the need for the virus to minimise host cell lysis, which would not only 
promote inflammation and the activation of antiviral immune cells, but also lead to the release of free 
virus particles that are susceptible to neutralization by anti-EV antibodies. One mechanism by which 
this may be avoided is suggested by recent evidence that HEVs, including CVB3, can be shed from 
cells within extracellular vesicles [71,72]. In principle, this could shield the virions from neutralizing 
antibodies and provide a means by which they can evade immune surveillance.   
Tackling HEV infection in individuals with, or who are at-risk of developing, T1D 
Two main strategies are being explored to tackle HEV infection in T1D; vaccination and treatment with 
anti-viral agents. Both have the potential to slow disease progression, yet each also has significant 
obstacles that must be overcome before it could be utilized in clinical practice. Islet autoimmunity in 
at-risk children peaks at two different ages and the specificity of the first autoantibody also differs at 
each age [73]. The first peak of autoimmunity occurs during the second year of life and is associated 
with the development of insulin autoantibodies (IAA), while the second is seen between 3-5y and is 
associated preferentially with the emergence of GADA autoantibodies [73]. Given that these initial 
signs of islet autoimmunity occur early in life, children would probably need to be vaccinated within 
the first few months of life in order to offer effective protection against HEV infection. This will require 
the development of safe and effective vaccines that can target multiple HEVs associated with the disease 
and there is precedent for this approach given the proven success of neonatal vaccination against 
poliomyelitis (another enterovirus). Moreover, encouraging progress has already been made on this 
front, with a new formalin-inactivated CVB1 vaccine successfully developed and tested in animal 
models [74-76]. Multivalent CVB1-6 vaccines are also now being generated (Hytönen and Flodström-
Tullberg, personal communication). Epidemiological data support the idea that a vaccination approach 
might be effective as a means to reduce the incidence of T1D since Finnish children infected early in 
life with CVB3 or CVB6 appear to be immuno-protected against a subsequent infection with different 
HEVs which might, otherwise, precipitate T1D [7].  Based on such evidence, one company, 
“Provention” has recently announced exciting plans to launch a first phase clinical trial to assess the 
safety and efficacy of a CVB vaccine in humans, with the intention of developing an effective approach 
to reduce the incidence of T1D (www.proventionbio.com).  
Alternative approaches also being explored include the development of virus like particles (VLPs) as 
antigens. These resemble the viral capsid of HEVs but do not contain infectious genome [77]. Vaccines 
and / or VLP rely predominantly on the host developing neutralizing antibodies against virus. These 
will therefore be most effective when given to individuals prior to any exposure to diabetogenic viruses 
and will hopefully ensure that the immune response is sufficiently robust to prevent the spread of 
infectious virus to the pancreas. What, though, might be done to tackle infection in people who already 
have evidence of islet autoimmunity and/ or clinical diabetes and who may be harbouring a persistent 
infection? 
This could be a fertile realm for anti-viral agents; although at the present time very little is known about 
whether these are effective against persistent enteroviral infections. Anti-viral agents are available 
(many of which have been re-purposed from other use in other conditions), or are in development, that 
are effective against HEVs associated with T1D (comprehensively reviewed recently in [78]), but the 
majority of these have been tested only under acute infection settings. These agents can be subdivided 
into two broad categories; those that target viral proteins and others which affect host proteins required 
for efficient viral replication, translation and release. Examples of the former include pleconaril which 
targets the viral capsid (reviewed in [79]); fluoxetine, commonly known as Prozac, which inhibits the 
viral protease 2C; and Gemcitabine, which binds to the viral RNA-dependent RNA polymerase, 3Dpol 
[80]., The second group includes Enviroxime, which targets the PI4K pathway [79]. Encouragingly, 
recent evidence has suggested that fluoxetine is effective against persistent enteroviral infection in cell 
models [81], but more research is required to test the activity of other drugs in this setting. Extensive 
efforts are underway to identify new anti-viral agents and these are aided by an increasing knowledge 
of the structure and function of viral proteins, as well as the identification of essential host factors. A 
further avenue of exploration is the use of combinations of different anti-viral agents that have additive 
or synergistic responses, which together can increase anti-viral potency, minimise the emergence of 
resistance and reduce drug toxicity/ side effects. This could be achieved by, for example, combining 
one drug that targets a viral protein, with another that targets an essential host factor. Alternatively, 
since it is well established that some anti-viral drugs have a low barrier to resistance (meaning that a 
single mutation within the virus can rapidly lead to drug resistance) whereas, for others, this is much 
higher, a combination approach employing each type of reagent might also yield clinical benefit.  
In summary, evidence for a viral aetiology in T1D is a long-established concept that has remained 
unproven. Nevertheless, supportive evidence continues to emerge at increasing pace and effective 
strategies which would minimize the risks deriving from HEV infection in susceptible individuals are 
being developed with increasing momentum. Arguably, it is only when the outcomes of these studies 
are known that it will be possible to confirm once-and-for-all whether T1D has an enteroviral 
component.  
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Figure Legends 
Figure 1: A model for CVB entry into beta cells via a specific CAR isoform, CAR-SIV. Recent data 
demonstrate that CAR-SIV is present at high levels on insulin secretory granules. Based on its structural 
organization, we predict that the C-terminus (CT) of CAR-SIV faces the cytoplasmic environment and 
importantly, the putative “extracellular domain” (ECD) which is required for the binding of 
enteroviruses, faces the granule lumen during biogenesis and maturation. This suggests that during 
exocytosis of insulin, the extracellular domain of CAR-SIV will be displayed on the external face of 
the plasma membrane and would then be available to bind to enteroviruses. During subsequent 
endocytosis of the granule membrane for recycling, the virus would be transported inside the cell, where 
it could initiate infection. 
Figure 2: A model of different beta cell responses to HEV infection. Following an infection with a 
HEV, systemic release of interferons primes the pancreas to respond to the likelihood of a local viral 
infection. (A) In most individuals this will lead to the induction of an anti-viral defence program which 
prevents the development of a sustained and productive infection of the beta cells. The virus is cleared 
and the host wins the battle.  (B) In some individuals (possibly neonates?) who have an impaired anti-
viral defence, enterovirus enters the cells and utilises critical host factors to establish a productive, lytic, 
infection. This can result in the release of free virus and/or viral and beta cell specific antigens. In 
individuals who are genetically predisposed to T1D, this damage may trigger the activation of islet 
autoreactive immune cells. (C) If the the host anti-viral defence program only partially inhibits viral 
replication, then a persistent infection might develop. Persistent infections are associated with 5’UTR 
deletions of the viral genome and the formation of dsRNA. dsRNA can activate host pathogen 
recognition receptors (PRRs) such as Mda5 (encoded by IFIH1) and stimulate an enhanced interferon 
signature in cells. This will, in turn, lead to the upregulation of HLAI and enhanced presentation of beta 
cell and viral antigens at the cell surface. In “at-risk” individuals this might then result in destruction 
by auto-reactive immune cells. Virus could be disseminated to other cells via extracellular vesicles, 
although this remains to be determined for human beta cells.  
 
 Table 1: Examples of enterovirus serotypes associated with Type 1 diabetes or/ and have 
ability to infect human islets in vitro 
 Reference 
General EV [9,12,18,82-88] 
CVB1-6 [7,8,32,33,35,38,39,89-96] 
Echovirus 3, 4, 6, 9, 16, 30 [91,97-107] 
Coxsackie A [107] 
 
  
Table 2: Relevant enteroviral receptors and their expression in human beta cells/ islets. 
Potential 
Enterovirus 
Receptors & 
Role [78]  
Enteroviruses that 
utilise these receptors 
Transcriptomic 
data suggesting 
expression in beta 
cells*  
Protein expression in 
islets** 
CAR 
Uncoating 
Coxsackievirus  B1-6 +++ +++ [40] 
DAF (CD55) 
Attachment 
Coxsackievirus 
A21, B1, B3 & B5 
Echovirus 3, 6, 7, 11-
13, 20, 21, 25, 29, 30 
++ HPA - Not detected; [41] 
ICAM1 
Uncoating 
 
Coxsackievirus A13, 
A18, A21 
Rhinovirus Major group 
(91 serotypes) 
Low 
HPA - Not detected in 
healthy controls; some 
evidence of upregulation 
in inflamed T1D islets 
[108] 
ICAM5 
Uncoating 
Enterovirus  D68 Negative HPA - Not detected 
SCARB2 
Uncoating 
Enterovirus 71 
Coxsackievirus A16 
+++ HPA - ++ 
PSGL1 
Attachment 
Enterovirus 71 
Coxsackievirus A16 
Negative HPA -Not detected 
α2β1 (VLA2) 
Attachment 
Echovirus 1, 8 
ITGA2 - Negative 
ITGB1 - +++ 
HPA -Not detected 
α5β3  
Attachment 
Coxsackievirus A9, 
Echovirus 1, 9 
ITGA5 - Negative 
ITGB3 - Negative 
HPA - Not detected 
+ in isolated islets [41] 
CAR – Coxsackie and adenovirus receptor; DAF – Complement decay accelerating factor; ICAM1 – 
Intercellular adhesion molelcule-1; SCARB2 – scavenger receptor class B member 2; PSGL1 – P-
selectin glycoprotein ligand 1; VLA2 – very late antigen 2. *Source: Transcriptomics of human islets. 
http://sandberg.cmb.ki.se/pancreas/; ** Source: Human Protein Atlas (HPA) or references. 
https://www.proteinatlas.org/  
 
Information for annotated references: 
 
(••) (2) Thomas et al; This study used a Type 1 diabetes genetic risk score to demonstrate 
that almost half of cases of Type 1 diabetes represented in the UK Biobank were 
diagnosed between 31-60y of age. These individuals are frequently misdiagnosed with 
Type 2 diabetes and receive inappropriate therapy. 
 
(•) (13) Lundberg et al; Demonstrates the presence of an interferon signature at the 
transcriptomic level using laser capture microdissected islets from recent-onset Type 1 
diabetes patients. 
 
(•) (14) Richardson et al; This study describes how a hallmark feature of Type 1 diabetes, 
hyperexpression of HLAI within insulin-containing islets, is associated with expression 
of STAT1. 
 
(••) (16) Genoni et al; Describes the development of a technique to identify the presence 
of chronic (persistent) enterovirus infection in human samples. 
 
(•) (21) Nyalwidhe et al; Utilised unbiased proteomic approaches to characterize the 
impact of CVB4 infection on human islets. 
 
(•) (22) Nyalwidhe et al; Proteomic study of LCM islets from controls, autoantibody 
positive and T1D donors identifying key proteins and pathways involved in disease 
pathogenesis. 
 
(••) (35) Hodik et al; Demonstrates the presence of viral replication complexes in close 
association with secretory granules in enterovirus infected beta cells.  
 
(••) (40) Ifie et al; Reports the expression of a specific isoform of CAR in human beta 
cells and its unique localisation within the insulin secretory granule, which could have 
important implications for the mechanism of enterovirus infection. 
 
(••) (42) Staring et al; This study identifies PLA2G16 as an essential host factor required 
for enterovirus genome release. 
 
(••) (61) Domsgren et al; Demonstrates that a common IFIH1 polymorphism associated 
with Type 1 diabetes alters the way human islets respond to CVB-infection. The risk 
variant was associated with increased expression of type III interferons.  
 
(••) (75) Stone et al; This work describes the testing of a new CVB1 vaccine in diabetes 
relevant rodent models and provides proof-of-concept for further studies in humans.  
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